METASTATIC PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug JSB462 tested for advanced prostate cancer in japanese patients
Disease control OngoingThis early-stage study tests a new drug called JSB462 (Luxdegalutamide) in 15 Japanese men whose prostate cancer has spread to other parts of the body. The main goal is to check the drug's safety and how the body processes it. Participants take the drug once daily with food.
Matched conditions: METASTATIC PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Prostate cancer protein map could guide future treatments
Knowledge-focused OngoingThis study examines 15 proteins on prostate cancer cells from 1,600 patients to see which ones are common and whether they relate to survival. Researchers will analyze stored tissue samples and collect new ones from men with advanced cancer. The goal is to understand these protei…
Matched conditions: METASTATIC PROSTATE CANCER (MCRPC)
Sponsor: Peking University First Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC